COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL COCO BUBU More..
Remdesivir study #20 of 20
3/20 Late treatment study
Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21 (Peer Reviewed)
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
Source   PDF   Share   Tweet
Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.

Mahajan et al., 3/20/2021, Randomized Controlled Trial, India, South Asia, peer-reviewed, 3 authors.
risk of death, 76.5% higher, RR 1.76, p = 0.47, treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).
risk of mechanical ventilation, 111.8% higher, RR 2.12, p = 0.42, treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 20 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.